Oruka Therapeutics, Inc. (ORKA)
ORKA moved a median of -0.03% 30 minutes after news, and +0.38% by the close. How ORKA actually reacts to news — the realized, point-in-time move the market made, measured across 199 labeled events over the last three years with zero look-ahead.
ORKA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 195 |
| 30-min | -0.03% | 50% | 196 |
| 60-min | +0.22% | 60% | 197 |
| to close | +0.38% | 54% | 192 |
| Middle 50% of ORKA reactions | -1.44% to +1.25% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 199 |
Half of all Oruka Therapeutics, Inc. news events land between -1.44% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ORKA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 43 | -0.22% | 35% | -0.60% |
| Rating reiterations | 71 | -0.81% | 39% | -0.45% |
| Price-target raises | 11 | +0.29% | 64% | +2.03% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ORKA ranks against every other measured name →
That’s how ORKA usually reacts — get an email when it moves on news →Email me when ORKA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ORKA's baseline. Nothing else.
Recent ORKA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing | Press release | GlobeNewswire | -0.11% | -4.42% | |
| Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference | Press release | GlobeNewswire | +0.01% | +1.60% | |
| Form EFFECT Oruka Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.89% | -4.14% | |
| Form 8-K Oruka Therapeutics, Inc. For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | -2.79% | |
| Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer | Press release | GlobeNewswire | +0.76% | -2.79% | |
| Form S-3 Oruka Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.21% | -4.06% | |
| Form 8-K Oruka Therapeutics, Inc. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | — | |
| Form 8-K Oruka Therapeutics, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | -3.30% | |
| Form 8-K Oruka Therapeutics, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +1.56% | |
| Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.07% | +0.45% | |
| Form 10-Q Oruka Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.85% | +0.85% | |
| Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.85% | +0.85% | |
| Form 8-K Oruka Therapeutics, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -8.97% | |
| Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering | Press release | GlobeNewswire | -4.05% | -10.79% | |
| Form 8-K Oruka Therapeutics, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | -15.14% | |
| Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis | Press release | GlobeNewswire | -3.33% | -15.14% | |
| Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering | Press release | GlobeNewswire | +6.98% | -5.40% | |
| Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 | Press release | GlobeNewswire | -3.33% | -15.14% | |
| Form ARS Oruka Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.32% | +0.54% | |
| Form DEF 14A Oruka Therapeutics, Inc. For: Jun 02 | SEC filing · Form DEF | SEC EDGAR | +0.32% | +0.54% | |
| Form DEFA14A Oruka Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.32% | +0.54% | |
| Form EFFECT Oruka Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.70% | +2.03% | |
| Form S-3 Oruka Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +3.76% | +2.49% | |
| Form 10-K Oruka Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.35% | +21.80% | |
| Form S-8 Oruka Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +4.35% | +21.80% | |
| Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.35% | +21.80% | |
| Oruka Therapeutics to Participate in Multiple Upcoming Conferences | Press release | GlobeNewswire | -1.71% | -1.86% | |
| Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 | Press release | GlobeNewswire | -2.31% | +10.63% | |
| Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.94% | -0.71% | |
| Form 8-K Oruka Therapeutics, Inc. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +0.37% | |
| Oruka Therapeutics Announces New Board Member and Board Transition | Press release | GlobeNewswire | -0.27% | +0.37% | |
| Form 10-Q Oruka Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.48% | — | |
| Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -6.48% | — | |
| Oruka Therapeutics to Present at Multiple November Investor Conferences | Press release | GlobeNewswire | -0.62% | +0.62% | |
| Form S-3/A Oruka Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.71% | -0.36% | |
| Form S-3 Oruka Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.15% | +2.73% | |
| Form 8-K Oruka Therapeutics, Inc. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | -9.59% | |
| Oruka Therapeutics Announces $180 Million Private Placement | Press release | GlobeNewswire | +0.44% | -8.88% | |
| Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 | Press release | GlobeNewswire | +0.44% | -8.88% | |
| Form 10-Q Oruka Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.57% | — | |
| Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.57% | — | |
| Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September | Press release | GlobeNewswire | +1.88% | -5.68% | |
| Form 8-K Oruka Therapeutics, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +5.08% | |
| Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer | Press release | GlobeNewswire | +0.08% | +5.08% | |
| Form 8-K Oruka Therapeutics, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +3.19% | -2.10% | |
| Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -1.09% | +0.47% | |
| Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody | Press release | GlobeNewswire | -1.09% | +0.47% | |
| Form 10-Q Oruka Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -7.05% | -9.82% | |
| Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -7.05% | -9.82% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ORKA section they belong to.
Where else ORKA is measured.
ORKA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oruka Therapeutics, Inc.'s median reaction calculated?
Every labeled ORKA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 199 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ORKA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ORKA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.